Peter Hulick to Humans
This is a "connection" page, showing publications Peter Hulick has written about Humans.
Connection Strength
0.483
-
The integration of personalized medicine into health systems: progress and a path forward. Per Med. 2021 09; 18(6):527-531.
Score: 0.026
-
Implementing Primary Care Mediated Population Genetic Screening Within an Integrated Health System. J Am Board Fam Med. 2021 Jul-Aug; 34(4):861-865.
Score: 0.025
-
Patient-Reported Outcomes and Experiences with Population Genetic Testing Offered Through a Primary Care Network. Genet Test Mol Biomarkers. 2021 Feb; 25(2):152-160.
Score: 0.025
-
Pharmacogenomics: Prescribing Precisely. Med Clin North Am. 2019 Nov; 103(6):977-990.
Score: 0.022
-
Cancer genetic testing panels for inherited cancer susceptibility: the clinical experience of a large adult genetics practice. Fam Cancer. 2014 Dec; 13(4):527-36.
Score: 0.016
-
Physicians' preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genet Test Mol Biomarkers. 2013 Mar; 17(3):219-25.
Score: 0.014
-
Cytogenetic and array-CGH characterization of a complex de novo rearrangement involving duplication and deletion of 9p and clinical findings in a 4-month-old female. Cytogenet Genome Res. 2009; 126(3):305-12.
Score: 0.011
-
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017 07 01; 109(7).
Score: 0.010
-
Effects of Social Determinants and Pharmacogenetic Medication Interactions on 90-Day Hospital Readmissions. Ann Fam Med. 2024 Nov 01; 21(Suppl 3).
Score: 0.008
-
Multicenter development and validation of a risk stratification tool for ward patients. Am J Respir Crit Care Med. 2014 Sep 15; 190(6):649-55.
Score: 0.008
-
Utility of Polygenic Scores for Differentiating Diabetes Diagnosis Among Patients With Atypical Phenotypes of Diabetes. J Clin Endocrinol Metab. 2023 Dec 21; 109(1):107-113.
Score: 0.008
-
Cancer-associated thrombosis by cancer sites and inherited factors in a prospective population-based cohort. Thromb Res. 2023 09; 229:69-72.
Score: 0.007
-
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2. Br J Cancer. 2023 06; 128(12):2283-2294.
Score: 0.007
-
Association of Reported Candidate Monogenic Genes With Lung Cancer Risk. Clin Lung Cancer. 2023 06; 24(4):313-321.
Score: 0.007
-
Refining Risk for Alzheimer's Disease Among Heterozygous APOE?4 Carriers. J Alzheimers Dis. 2023; 94(2):483-489.
Score: 0.007
-
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers. Commun Biol. 2022 10 06; 5(1):1061.
Score: 0.007
-
Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies. Prostate Cancer Prostatic Dis. 2022 09; 25(3):422-430.
Score: 0.007
-
Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet. 2022 03; 30(3):349-362.
Score: 0.007
-
Physician-directed genetic screening to evaluate personal risk for medically actionable disorders: a large multi-center cohort study. BMC Med. 2021 08 18; 19(1):199.
Score: 0.006
-
Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort. Prostate. 2021 09; 81(13):1002-1008.
Score: 0.006
-
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genet Med. 2021 09; 23(9):1726-1737.
Score: 0.006
-
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021 02 17; 12(1):1078.
Score: 0.006
-
Calibration of polygenic risk scores is required prior to clinical implementation: results of three common cancers in UKB. J Med Genet. 2022 03; 59(3):243-247.
Score: 0.006
-
Cystic fibrosis F508del carriers and cancer risk: Results from the UK Biobank. Int J Cancer. 2021 04 01; 148(7):1658-1664.
Score: 0.006
-
Flype: Software for enabling personalized medicine. Am J Med Genet C Semin Med Genet. 2021 03; 187(1):37-47.
Score: 0.006
-
Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. Eur Urol. 2021 03; 79(3):419-426.
Score: 0.006
-
Mutations of the Transcriptional Corepressor ZMYM2 Cause Syndromic Urinary Tract Malformations. Am J Hum Genet. 2020 10 01; 107(4):727-742.
Score: 0.006
-
Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank. Br J Cancer. 2020 10; 123(9):1356-1359.
Score: 0.006
-
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). JAMA Oncol. 2020 08 01; 6(8):1218-1230.
Score: 0.006
-
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med. 2020 10; 22(10):1653-1666.
Score: 0.006
-
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet. 2020 06; 52(6):572-581.
Score: 0.006
-
Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. Genet Epidemiol. 2020 07; 44(5):442-468.
Score: 0.006
-
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nat Genet. 2020 01; 52(1):56-73.
Score: 0.006
-
Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Res. 2020 02 01; 80(3):624-638.
Score: 0.006
-
Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Med. 2019 09; 8(12):5609-5618.
Score: 0.006
-
BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. Hum Mutat. 2019 10; 40(10):1781-1796.
Score: 0.006
-
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 07; 121(2):180-192.
Score: 0.006
-
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nat Commun. 2019 04 15; 10(1):1741.
Score: 0.005
-
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. J Natl Cancer Inst. 2019 04 01; 111(4):350-364.
Score: 0.005
-
De novo variants in HK1 associated with neurodevelopmental abnormalities and visual impairment. Eur J Hum Genet. 2019 07; 27(7):1081-1089.
Score: 0.005
-
Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 01 25; 10(1):431.
Score: 0.005
-
A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res. 2018 09 15; 78(18):5419-5430.
Score: 0.005
-
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat. 2018 05; 39(5):593-620.
Score: 0.005
-
Patient perspectives following pharmacogenomics results disclosure in an integrated health system. Pharmacogenomics. 2018 03; 19(4):321-331.
Score: 0.005
-
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017 Dec; 49(12):1767-1778.
Score: 0.005
-
Primary care physician experiences with integrated pharmacogenomic testing in a community health system. Per Med. 2017 09; 14(5):389-400.
Score: 0.005
-
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May; 49(5):680-691.
Score: 0.005
-
Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. Eur J Hum Genet. 2017 04; 25(4):432-438.
Score: 0.005
-
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur Urol. 2017 05; 71(5):740-747.
Score: 0.005
-
Implementation of a multidisciplinary pharmacogenomics clinic in a community health system. Am J Health Syst Pharm. 2016 Dec 01; 73(23):1956-1966.
Score: 0.005
-
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat. 2017 01; 161(1):117-134.
Score: 0.005
-
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun. 2016 09 07; 7:12675.
Score: 0.005
-
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS One. 2016; 11(7):e0158801.
Score: 0.005
-
Patient satisfaction with nipple-sparing mastectomy: A prospective study of patient reported outcomes using the BREAST-Q. J Surg Oncol. 2016 Sep; 114(4):416-22.
Score: 0.005
-
Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res. 2016 06 21; 18(1):64.
Score: 0.004
-
History repeats itself: the family medication history and pharmacogenomics. Pharmacogenomics. 2016 05; 17(7):669-78.
Score: 0.004
-
Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. Am J Hum Genet. 2016 05 05; 98(5):830-842.
Score: 0.004
-
Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. Hum Mol Genet. 2016 06 01; 25(11):2256-2268.
Score: 0.004
-
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet. 2016 Apr; 48(4):374-86.
Score: 0.004
-
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016 Feb 09; 18(1):15.
Score: 0.004
-
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2016 Feb; 108(2).
Score: 0.004
-
Diagnostic Exome Sequencing Identifies a Novel Gene, EMILIN1, Associated with Autosomal-Dominant Hereditary Connective Tissue Disease. Hum Mutat. 2016 Jan; 37(1):84-97.
Score: 0.004
-
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Apr 07; 313(13):1347-61.
Score: 0.004
-
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Nov; 148(2):397-406.
Score: 0.004
-
Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature. Ann Surg Oncol. 2015 Feb; 22(2):370-6.
Score: 0.004
-
Variable clinical presentation of an MUC1 mutation causing medullary cystic kidney disease type 1. Clin J Am Soc Nephrol. 2014 Mar; 9(3):527-35.
Score: 0.004
-
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol. 2014 Sep; 66(3):489-99.
Score: 0.004
-
Human folliculin delays cell cycle progression through late S and G2/M-phases: effect of phosphorylation and tumor associated mutations. PLoS One. 2013; 8(7):e66775.
Score: 0.004
-
A public resource facilitating clinical use of genomes. Proc Natl Acad Sci U S A. 2012 Jul 24; 109(30):11920-7.
Score: 0.003
-
Bernard-Soulier syndrome: common ancestry in two African American families with the GP Ib alpha Leu129Pro mutation. Am J Hematol. 2000 Oct; 65(2):141-8.
Score: 0.002